VTE in pregnancy
Risk ↑~10× antepartum, ~15–35× per day in the first 6 wk postpartum. Suspected PE: pregnancy-adapted YEARS + D-dimer can exclude PE in low/intermediate probability — high suspicion → empiric LMWH + imaging. Treat with weight-based LMWH ≥3 months total and ≥6 wk postpartum. No DOACs in pregnancy or breastfeeding. Prior unprovoked or oestrogen/pregnancy-related VTE → antepartum + 6 wk postpartum prophylaxis.
suspected PE — pregnancy-adapted YEARS
%%{init: {"flowchart": {"nodeSpacing": 24, "rankSpacing": 32, "wrappingWidth": 260}}}%%
flowchart TD
A["suspected PE in pregnancy"] --> B(["haemodynamically unstable?"])
B -->|"yes"| C["bedside echo, CTPA if feasible<br>UFH, consider reperfusion"]
B -->|"no"| D(["DVT signs or symptoms?"])
D -->|"yes"| E["compression US"]
E -->|"DVT"| F["treat — no chest imaging"]
E -->|"no DVT"| G
D -->|"no"| G["YEARS items: DVT signs,<br>haemoptysis, PE most likely"]
G -->|"0 items"| H["cut-off 1000 µg/L FEU"]
G -->|"≥ 1 item"| I["cut-off 500 µg/L FEU"]
H --> L(["D-dimer below cut-off?"])
I --> L
L -->|"yes"| J["PE excluded"]
L -->|"no"| K["CTPA or V/Q"]
- Start therapeutic LMWH while awaiting imaging if suspicion high and no bleeding contraindication
- Thresholds are FEU — confirm local assay units (DDU values are ~half)
- Most useful early: ARTEMIS avoided CTPA in 65% in T1 vs 32% in T3
- Alternative validated pathway: Geneva score + D-dimer + CUS (CT-PE-Pregnancy (2018))
- DVT in pregnancy: >80% left-sided, often isolated iliofemoral → back/buttock/flank pain; CUS negative + high suspicion → iliac Doppler or MRV — see deep vein thrombosis
34 wk, pleuritic pain, HR 130, SpO₂ 90–95%, raised JVP, post long-haul flight → high pretest probability. Start LMWH now and image (CTPA or V/Q). D-dimer <500 does not exclude PE here. Negative leg US doesn’t exclude PE. LMWH, not a DOAC.
imaging choice
| CTPA | V/Q (perfusion-only possible) | |
|---|---|---|
| foetal dose | very low | very low (slightly higher than CTPA) |
| maternal breast dose | higher | lower |
| best when | abnormal CXR, need alternative diagnosis, V/Q unavailable | normal CXR, available — often preferred (lower breast dose); TC leaves the choice to availability, expertise and patient preference |
| non-diagnostic rate | higher in pregnancy (contrast dilution) | indeterminate results possible |
- Both far below the 50 mGy threshold for foetal harm — missing PE is the bigger risk
- Iodinated contrast: don’t withhold; neonatal TSH check per local practice
- Postpartum: investigate as non-pregnant. CT contrast compatible with breastfeeding; V/Q isotope may contaminate breast milk for 24–48 h (TC) — pump and discard per nuclear medicine
treatment
| agent | therapeutic dose |
|---|---|
| enoxaparin | 1 mg/kg SC q12h (or 1.5 mg/kg daily) |
| dalteparin | 200 U/kg SC daily (or 100 U/kg q12h) |
| tinzaparin | 175 U/kg SC daily |
| UFH IV | when reversal/rapid offset needed — massive PE, near delivery, high bleeding risk, CrCl <30 |
- Duration: ≥3 months total and until ≥6 wk postpartum
- Dose by weight at diagnosis (adjusting through pregnancy is controversial); once daily preferred for convenience (TC); routine anti-Xa not recommended (ASH) — consider at weight extremes, renal impairment, recurrent VTE
- Warfarin: embryopathy T1 (6–12 wk), CNS anomalies/foetal bleeding later → avoid except mechanical valves; fine postpartum and breastfeeding
- DOACs: cross placenta → avoid; avoid in breastfeeding
- HIT on heparin: danaparoid first line (TC; very limited fondaparinux data in pregnancy). HIT is rare with LMWH in pregnancy — no routine platelet monitoring; with haematology/thrombosis input — see heparin-induced thrombocytopaenia
- Massive PE: thrombolysis (alteplase doesn’t cross placenta), catheter-directed therapy, or surgical embolectomy — pregnancy is not a contraindication when life-threatening
- IVC filter: only if acute VTE and anticoagulation contraindicated; consider retrievable filter if acute PE within 2 wk of delivery; retrieve postpartum
peripartum anticoagulation
| on | stop before neuraxial / planned delivery | restart postpartum |
|---|---|---|
| prophylactic LMWH | ≥12 h | ≥4 h after catheter removal; 4–6 h post vaginal, 6–8 h post CS if haemostasis |
| therapeutic LMWH | ≥24 h | prophylactic dose ≥12 h after delivery/epidural removal (TC), therapeutic once haemostasis secure (usually ≥24 h) |
| IV UFH | 4–6 h | — |
- Planned delivery (induction/CS) if on therapeutic dose; written plan with obstetrics, anaesthesia, haematology
- VTE within 2–4 wk of delivery → consider IV UFH peripartum; consider IVC filter
- Spontaneous labour on LMWH → stop and assess timing with anaesthesia
thromboprophylaxis
prior VTE
| prior VTE | antepartum | 6 wk postpartum |
|---|---|---|
| unprovoked | ✓ | ✓ |
| oestrogen- or pregnancy-related | ✓ | ✓ |
| provoked by major transient non-hormonal factor (surgery, trauma) | ✗ (surveillance) | ✓ |
| on long-term anticoagulation | therapeutic LMWH | resume long-term agent |
no prior VTE, known thrombophilia (ASH 2018)
| thrombophilia | antepartum | 6 wk postpartum |
|---|---|---|
| homozygous FVL, combined thrombophilia | ✓ | ✓ |
| antithrombin deficiency | ✓ if family history | ✓ if family history |
| homozygous PT G20210A | ✓ if family history | ✓ |
| protein C or S deficiency | ✗ | ✓ if family history |
| heterozygous FVL or PT G20210A | ✗ | ✗ (even with family history) |
| obstetric APS | ✓ + aspirin 81 mg | ✓ (6 wk) |
| thrombotic APS | therapeutic LMWH + aspirin | resume warfarin |
- Doses: enoxaparin 40 mg daily, dalteparin 5000 U daily, tinzaparin 4500 U daily; obesity (SOGC 308) → enoxaparin 60 mg daily, dalteparin 7500 U daily, tinzaparin 75 U/kg daily; TC: ≥100–120 kg → intermediate dose (enoxaparin 40 mg BID or 80 mg OD, dalteparin 5000 U BID or 10 000 U OD, tinzaparin 10 000 U OD)
- No anti-Xa monitoring on prophylactic doses
- Prior oestrogen-related VTE: ~5–10% recurrence risk in pregnancy without prophylaxis
- Postpartum prophylaxis also for CS with risk factors (preeclampsia + FGR, BMI >30, emergency CS, multiples, smoking) — obstetric risk tools
- Don’t routinely test for thrombophilia — only if result changes management; protein S falls in normal pregnancy. See hereditary thrombophilia, antiphospholipid syndrome
Avoid oestrogen-containing methods after VTE. Options: LNG-IUD, copper IUD, etonogestrel implant, progestin-only pill, tubal ligation.
evidence
- ARTEMIS (2019) — n=498 managed by pregnancy-adapted YEARS; 3-mo VTE 0.21%; CTPA avoided in 39% (65% T1, 32% T3)
- CT-PE-Pregnancy (2018) — Geneva + D-dimer + CUS + CTPA; 3-mo VTE 0%
- Bellesini, J Thromb Haemost. 2021 — D-dimer pooled sensitivity ~99.5% in pregnancy when used in low/intermediate probability
Prepared 2026-10-21. Not yet verified — check every number against the sources.
Key references
- guidelineChan WS, et al. SOGC Guideline No. 308: Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can. 2014;36(6):527-553.